Name of leader and affiliation
Justin Green, DDW Programme

GlaxoSmithKline (GSK) is a major international pharmaceutical company dedicated to bringing effective medicines to patients. GSK has a heritage and expertise in researching and developing new medicines and vaccines and is committed to searching for new treatments for many of the diseases that affect millions of people in some of the world´s least well off nations. Technical and scientific resources GSK is devoting to this important area include a specialized research centre in Spain (Diseases of Developing World Medicines Development Centre, DDW MDC) which carries out research into global health priorities like malaria and tuberculosis. DDW MDC has a strong experience in research of new anti-infective and is equipped with state-of-the-art BSL3 facilities to work in vitro and in vivo with pathogenic bacteria and parasites. We are currently working under private-public partnership with groups including Medicines for Malaria Venture (MMV) and the Global Alliance for TB drug development (GATB).

Sorry, no posts found for this author.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.